BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, October 18, 2024
See today's BioWorld Asia
Home
» Celltrion’s Omlyclo gets nod as Europe’s first Xolair biosimilar
To read the full story,
subscribe
or
sign in
.
Celltrion’s Omlyclo gets nod as Europe’s first Xolair biosimilar
May 28, 2024
By
Marian (YoonJee) Chu
No Comments
South Korea’s Celltrion Inc. secured May 22 the European Commission’s go-ahead for Omlyclo (CT-P39) to be the first biosimilar to Genentech Inc./Novartis AG’s Xolair (omalizumab) in Europe for three of its major indications.
BioWorld Asia
Regulatory
Respiratory
Biosimilar
Monoclonal antibody
Asia-Pacific
Europe
China
BLA
CHMP
EMA
NMPA